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EXECUTIVE SUMMARY
Hypertensive disorders in pregnancy, experienced by 10 percent of women globally, are major contributors
to maternal and newborn mortality, morbidity, and disability. Task shifting essential health services to
mitigate insufficient human resources is recommended to strengthen and expand the health work force to
rapidly increase access to quality services. Nigeria’s task shifting policy recommends that community
health extension workers administer a loading dose of magnesium sulphate prior to referral for severe preeclampsia or eclampsia to a higher level facility. The success achieved with magnesium sulphate task
shifting to lower level health facilities has not been widely explored with anti-hypertensive drugs to control
high blood pressure in pregnant women.
This study tested the feasibility and acceptability of community health extension workers at primary
healthcare facilities in Ebonyi state to detect and manage pregnancy-associated hypertension using alpha
methyldopa and magnesium sulphate where appropriate and refer for follow up. Baseline data were
collected from 10 of 13 local government areas in 40 primary healthcare centers (20 interventions and 20
comparison) in 2016 and endline in November 2017.
In intervention arm only, community health extension workers were trained and mentored to detect, classify
and manage hypertension associated with pregnancy, pre-eclampsia and eclampsia and refer to their
affiliated secondary health facilities according to clinical protocols. For pregnant women identified with
hypertension with or without significant proteinuria, they were recruited into the study and subsequently
followed-up post-delivery. If a woman’s blood pressure was not controlled, women were referred to a higher
facility. For women with severe pre-eclampsia and eclampsia, they received a loading dose of magnesium
sulphate and were referred.
Community health extension workers in the comparison arm received no training or mentorship; and
continued with their usual practice of administering a loading dose of magnesium sulphate to women with
severe pre-eclampsia/eclampsia and referral.
More community health extension workers in the intervention arm correctly identified normal blood
pressure, and differentiated as well as managed, mild, moderate, and severe hypertension than those in
the comparison arm. This included a 72 percent knowledge improvement in when to introduce antihypertensives versus a three percent improvement in the comparison arm; and were three times more
likely to identify alpha methyldopa as a specific drug to control blood pressure at endline. Significant
differences were also observed in knowledge and ability to categorize the various hypertensive disorders
in pregnancy correctly. In both arms, community health extension workers were most likely to prescribe
alpha methyldopa (60% and 50% respectively) at endline. Among women with moderate-to-severe
hypertension who required anti-hypertensives upon diagnosis, more women in the intervention arm
received treatment than women in the comparison arm.
During the study, five maternal deaths occurred: one intrapartum death from the intervention arm and four
from the comparison arm (one antepartum, 2 intrapartum, one postpartum). The woman who died in the
intervention arm did not receive a loading dose of Magnesium Sulphate following diagnosis of severe preeclampsia (all women who received a loading dose survived). A total of 13 fetal deaths also occurred: four
in the intervention arm (3 stillbirths and one early neonatal death) and nine to the comparison arm (all
stillbirths). None of the mothers of the babies who died received a loading dose of magnesium sulfate.
Community health extension workers at primary health care facilities can correctly measure blood pressure,
detect abnormal blood pressure, and treat accordingly for severe pre-eclampsia and eclampsia, and refer
to a higher facility for further management. Although challenges remain in ensuring sufficient commodities
and supplies are continuously available, this study demonstrates how ministries of Health might use these
missed opportunities to detect pre-eclampsia (and potentially other conditions) and prevent deterioration
by providing anti-hypertensives and magnesium sulphate to stabilize and refer women.
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BACKGROUND
Hypertensive disorders in pregnancy (HDPs), experienced by 10 percent of women globally, are major
contributors to maternal and newborn mortality, morbidity, and disability1-2. HDPs include pre-eclampsia,
gestational hypertension (hypertension), and chronic hypertension during pregnancy. Pre-eclampsia,
defined as hypertension with significant proteinuria after 20 weeks’ gestation in pregnancy, complicates
two to eight percent of pregnancies3, 4. In low- and middle-income countries (LMICs), a woman is seven
times more likely to develop pre-eclampsia than a woman in a high income country. Some 10 percent to
25 percent of women who suffer from pre-eclampsia likely will die5, 6. About 10 percent of women with preeclampsia develop severe pre-eclampsia and eclampsia6-7. Of the 10 to 25 percent of the pre-eclampsia
and eclampsia (PE/E)-related maternal deaths worldwide, eclampsia accounts for about 14 percent5, 8.
In recent years, there has been increased recognition and support for the use of magnesium sulphate
(MgSO4) as a life-saving and cost-effective maternal health commodity, both as prophylaxis and treatment
for convulsions due to severe PE/E9-17. Similar attention has not been given to identifying and managing
hypertension associated with PE/E, as well as other forms of hypertension seen in pregnancy. Failure to
address hypertension minimizes the gains in institutionalizing MgSO4 in a health system for PE/E
management.
Globally, task shifting essential health services to accommodate insufficient human resources is
recommended for strengthening and expanding health workforces for rapid increases in access to quality
services18-19. Specific reorganization and decentralization recommended by the World Health Organization
(WHO) is due to the knowledge that lower level cadres such as auxiliary nurse and midwives can administer,
with targeted monitoring and evaluation (M&E), anti-hypertensive drugs for severe HDP19. Less, however,
is known about the abilities of community health extension workers—the main figures in primary health
care (PHC) in Nigeria—and their suitability to provide anti-hypertensive services. CHEWs are a lower level
service provider cadre with more training than an auxiliary nurse or midwife (as defined by WHO).
CHEWs in Nigeria receive three years of pre-service training and community experience, so it is conceivable
they could also be provided with appropriate knowledge, skills, and training for managing moderate and
severe hypertension using anti-hypertensive drugs recommended for use in pregnancy, and then referring
women to higher levels for follow up care, if appropriate.
In Nigeria, HDPs—principally PE/E—account for over 23 percent of deaths among pregnant women6.
Programs for averting PE/E mortality and morbidity have made MgSO4 routinely available, with some
success9,11,20. These efforts have also implemented task shifting for CHEW administration of a loading dose
of MgSO4 prior to referrals to a higher level facility for severe PE/E 20-21. The successes achieved with MgSO4
task shifting to lower level health facilities has not been widely transferred to anti-hypertensive drugs for
controlling high blood pressure (BP) in pregnant women prior to referral.
Rapidly increasing BP may result in cerebrovascular accident (CVA), a known cause of death in women with
PE/E. Addressing HDP in a timely and effective way reduces maternal morbidity and mortality, but emphasis
has varied on how to achieve this goal, with more attention to MgSO4 and less emphasis on studying the
administration of anti-hypertensive drugs21. Before 2013 in Nigeria, CHEWs at PHCs were not authorized
to administer MgSO4 for severe PE/E due to perceptions of insufficient training22. A quasi-experimental
pilot study in Kano state showed that MgSO4 task shifting (initial dose for women with severe PE/E, and
referral to secondary hospitals) to CHEWs at PHCs resulted in demonstrable improvements in maternal and
neonatal survival20. The study trained CHEWs, with one year of follow up, M&E, and supportive supervision.
Presentation of these findings at the 2012 National Council of Health (NCH) of Nigeria contributed to the
policy change allowing CHEWs to administer a loading dose of MgSO4 prior to referral.
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Although HDP treatment by PHC CHEWs is not recommended in Nigeria’s current national task shifting
policy, a 2015 analysis in seven Nigerian states, of service providers’ knowledge and practices, and
pregnant women’s and community members’ understanding, of PE/E found that 41 percent of PHC
providers (mainly CHEWs) reported prescribing anti-hypertensive drugs—some not recommended in
pregnancy—to pregnant women 23. It is imperative to provide appropriate anti-hypertensive drugs to
pregnant women with moderate to severe HDP, and at their first contact with the health system.
CHEWs are currently not authorized to prescribe anti-hypertensive drugs but can refer pregnant women
with high BP to a secondary hospital, although they may have the capacities to treat women on site21. This
is contrary to other countries’ practices and WHO recommendations for task shifting to lower level cadres1819. This study tested the feasibility and acceptability of Nigeria’s PHC CHEWs to detect and manage HDP
using alpha methyldopa, including administration of MgSO4 and referral to higher level care, where
appropriate.

STUDY GOALS AND OBJECTIVES
The overall aim of this study was to assess the feasibility and acceptability of CHEWs’ detection and
management of HDP using alpha methyldopa. The specific objectives were to:
 Assess the feasibility of CHEWs’ detection and classification of high BP among pregnant women

during antenatal care (ANC) contacts,
 Assess CHEWs’ abilities to prescribe an anti-hypertensive drug (alpha methyldopa) for pregnant

women with moderate hypertension, and
 Assess CHEWs’ abilities to prescribe appropriate an anti-hypertensives drug (alpha methyldopa)

for pregnant women with severe hypertension during PE/E prior to referral, including prescribing
and administering MgSO4 for severe PE/E prior to referral.
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METHODOLOGY
STUDY SETTING

EBONYI STATE, NIGERIA

This study was conducted in southeastern Nigeria’s Ebonyi
state, comprised of 13 local government areas (LGAs).
Ebonyi is one of the three states where Population Council
implemented the Ending Eclampsia project, a larger effort
supporting PE/E prevention, early detection, and
management at lower health system levels23. Ebonyi has
the worst health indices among Nigeria’s southeastern
states, similar to many northern states; but its level of
education is generally higher than the north, which makes
Ebonyi a conducive setting for this study.

 Total Population: 2.2 Million
(2006 census)
 ANC attendance: 85%
 Health facility deliveries: 60%
 Postnatal care within 48 hours
of delivery: 55%
 Mean age at first delivery: 21. 4
 Total fertility rate: 5.3
Source DHS 2013

Nigeria’s health system is designed for a secondary health care facility (i.e. hospital) in each LGA, to which
four PHC facilities are referring facilities. Ebonyi state has 13 secondary hospitals and 52 PHC facilities.
Statutorily, CHEWs staff all PHC facilities in Nigeria, including in Ebonyi state.

HOW INTERVENTIONS WERE OPERATIONALIZED
PHC CHEWs were trained and mentored by this study to detect, classify, and manage HDP, including
referring patients to affiliated secondary hospitals. Hypertensive disorders investigated included chronic
hypertension (defined as isolated hypertension diagnosed before the index pregnancy or detected before
20 weeks of gestation), gestational hypertension (isolated hypertension diagnosed for the first time after
20 weeks of index pregnancy without proteinuria), and pre-eclampsia (gestational hypertension and
proteinuria of ≥ ++ using a urine dipstick). Hypertension was defined as a systolic BP (sBP) of ≥140mmHg
and or diastolic BP (dBP) of ≥90mmHg measured on two different occasions, four to six hours apart. In
some cases, where distance was a factor, clients stayed at the facility for repeat measurement; if clients
lived nearby, they were instructed to return.
CHEWs were trained and mentored to correctly diagnose hypertension as chronic, gestational, or as PE/E.
Training also featured hypertension classification—as mild, moderate, or severe—and either pre-eclampsia
or severe pre-eclampsia. For mild hypertension, CHEWs were trained to only regularly monitor BP. For
moderate hypertension, CHEWs prescribe alpha methyldopa. For severe hypertension, in addition to
continued alpha methyldopa, CHEWs were advised to refer clients to a higher level facility, and if associated
with severe pre-eclampsia, CHEWs administered a loading dose of MgSO4 before referral (see Table 1).

FACILITY SELECTION AND CHEWS IDENTIFICATION AND TRAINING
In collaboration with Ebonyi state’s Ministry of Health (SMoH), Ending Eclampsia randomly selected 10
LGAs: five (featuring 20 PHC facilities) to serve as intervention sites and the other five (also with 20 PHCs)
as comparison sites. Both the intervention and comparison arms were already trained and authorized to
administer a loading dose of MgSO4 for severe PE/E. CHEWs conducting antenatal care (ANC) services in
the intervention arm were then also trained to detect and classify HDP, including treatment with alpha
methyldopa and a loading dose of MgSO4, when appropriate. CHEWs in the comparison arm received no
such training and mentorship, and were to continue usual practice, which includes administering a loading
dose of MgSO4 to women with severe PE/E, as recommended by the national task shifting policy, for
referring women with high BP during pregnancy.
4

Table 1: Diagnostic and management algorithm used for this study
Diagnosis

Chronic
Hypertension

Categories
Mild Hypertension
(140 – 149/ 90 – 99mmHg)
Moderate Hypertension
(≥150/100mmHg
but <160/110mmHg)
Severe Hypertension
(≥160/110mmHg)
140 – 149/ 90 – 99mmHg

Gestational
Hypertension

Pre-eclampsia

Moderate Hypertension
(≥150/100mmHg
But <160/110mmHg)
Severe Hypertension
(≥160/110mmHg)
Mild Hypertension
(140 – 149/ 90 – 99mmHg)
Moderate Hypertension
(≥150/100mmHg
But <160/110mmHg)
Severe Hypertension
(≥160/110mmHg)

Eclampsia

Monitor BP closely
No anti-hypertensive

Interventions

Instructions
Return in one week or when
no complaint

Introduce oral
methyldopa/Aldomet

Return in one week or when
no complaint

Oral methyldopa/
Aldomet
Monitor BP closely
No anti-hypertensive

Return in one week or when
no complaint

Introduce oral
methyldopa/Aldomet

Return in one week or when
no complaint

Refer to higher level facility

Oral methyldopa/
Aldomet
Monitor BP closely
No anti-hypertensive

Return in one week or when
no complaint

Introduce oral
methyldopa/Aldomet

Return in one week or when
no complaint

Oral methyldopa/
Aldomet
loading dose of MgSO4

Refer to higher level facility

Loading dose of MgSO4

Refer immediately to higher
level facility

Refer to higher level facility

In October 2016, CHEWs in the intervention arm attended a three day, competency-based training
workshop. A group of master trainers (MTs) and trainers selected from SMoH and Ob/Gyn and midwifery
professionals was established. Pre- and post-training tests assessed immediate changes in knowledge. The
training curriculum was based upon WHO as well as the national guidelines for HDP management 24.
Treatment protocols and a referral decision-making tree for HDPs (also developed based upon WHO
recommendations) were provided to CHEWs, to guide identification and treatment for women with HDPs.
The protocol and decision-making tree describe ways to identify HDP during ANC (and PNC) and to
categorize hypertension as chronic, gestational, or as pre-eclampsia. Furthermore, the guidelines provide
information for grading hypertension as mild, moderate, and severe, and management of each category.
Training also emphasized how to correctly determine BP, conduct urine protein testing with dipstick, and
when to administer anti-hypertensive drugs (alpha methyldopa, Aldomet), as well as counseling clients and
referral processes. CHEWs were also instructed how to document the essential elements of their ANC
services, for example BP and urine results, past medical history, gestational age, and identifying danger
signs and symptoms in pregnancy. Details of counseling and referral, including policy guidelines for referral
and the importance of adherence to referral, were emphasized. CHEWs were also oriented on the study
procedures, ethical issues, as well as the participant enrollment processes.
CHEWs in the comparison arm did not receive any training on HDP detection and management (other than
standard CHEW services in Nigeria, which includes administering a loading dose of MgSO4 to women with
severe PE/E, and referral).
CHEWs’ training on HDP diagnosis, classification, and management was based upon the algorithm shown
in Table 1
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Figure 1: Flow chart for diagnosing and management NTN in pregnancy for the study

Figure 1: Flow chart for diagnosing and managing hypertension in pregnancy for this study
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CLIENT IDENTIFICATION
Pregnant women attending an ANC clinic were screened for hypertension and proteinuria. For women with
high BP or significant proteinuria, CHEWs documented their socio-demographic characteristics, obtained
informed consent, and recruited them into the study. Only hypertensive pregnant women 15 years or older
were enrolled. Although the age of consent in Nigeria is 18 years, pregnant women younger than 18 are
considered emancipated by virtue of their pregnancy status. And in addition, the national policy for research
with adolescents indicates that adolescents can make informed decisions about their medical needs25.
CHEWs opened a treatment folder for each client, in which all clinical decisions and medical interventions
were documented. Each recruited client was followed until her delivery, and into the immediate postpartum
period (up to 48 hours) to determine if she was managed according to the guidelines. Permission for a
follow up call was obtained during the informed consent process.

CLIENT REFERRAL
Guided by the decision-making tree (job aid and treatment algorithm, see Figure 1), if a woman’s BP was
not controlled, she was referred to a physician at a secondary- or higher level facility. When a woman had
severe PE/E, she was administered a loading dose of MgSO4, according to the national standard, and
referred to a higher level facility for definitive management. CHEWs displayed job aids in their consultation,
treatment, and labor rooms for ease of reference.
To track referrals, CHEWs issued a duplicate copy of a client’s completed case notes for the client to take
to the referral facility; then, if a client did not present at a referral facility, the CHEW called the client or her
family directly. In the comparison arm, CHEWs were encouraged to refer clients with severe cases to higher
level facilities for definitive management, but they did not receive training on how to identify and manage
HDPs.

SUPPLY OF ANTI-HYPERTENSIVE DRUGS (ALPHA METHYLDOPA)
Before commencing the study, consultative meetings with Ebonyi SMoH requested their procurement,
supply, and monitoring of uptake of anti-hypertensive drugs (alpha methyldopa only) among the study’s
intervention facilities, staff, and clients. Initial doses of alpha methyldopa were prescribed by CHEWs and
obtained from facilities’ pharmacies. If stock outs occurred during the study, clients were asked to obtain
the drug at a local pharmacy (while efforts were being made to replenish facility supplies). Women were
instructed to return for prescription refills at the health facility; BP was re-checked at every visit.

CHEW SUPPORTIVE SUPERVISION AND JOB AIDS
Chews were monitored and mentored monthly, and clients’ records were reviewed during each monitoring
visit to ensure chew compliance with ethical and clinical standards. This monthly supportive supervision
was in collaboration with Ebonyi SMoH. A SMoH physician provided M&E and supervision for the
management of any adverse events of drugs. During supportive supervision visits, chews were observed
for how they measured and determined BP and tested for urine proteins. In instances with no incidences
of hypertension at a facility, chews were encouraged to explain the HDP treatment protocol and algorithm
(Figure 1).
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SAMPLING, DATA COLLECTION AND ANALYSIS
The study’s design was quasi-experimental and a non-equivalent comparison, in which 40 PHC facilities
from 10 LGAs were divided into two arms (5 LGAs in each arm)—experimental and comparison. Four PHC
facilities were selected within each, LGA for a total of 20 facilities per study arm. There were three periods
of data collection during implementation—at baseline in October 2016, immediate post-training in
November 2016, and endline in November 2017.
At baseline, a cross-sectional survey of health care providers’ (mainly CHEWs) knowledge and practices
was conducted in both study arms using a pre-tested, interviewer-administered questionnaire (October
2016). At the same time, a facility inventory determined availability of commodities and supplies for HDP
detection and management. Quarterly facility inventory reviews were conducted throughout the
intervention period in the intervention arm.
After CHEWs in the intervention arm were trained on HDP detection and management in November 2016,
a post-training test determined any change in their knowledge of HDPs.
At endline, in November 2017, a provider survey of the trained CHEWs arm assessed their knowledge
retention. All case notes from enrolled clients were retrieved and reviewed to determine how clients were
identified, classified, and managed, in addition to the quality of care provided by CHEWs.
Lastly, in November 2017 in-depth interviews (IDIs) with women diagnosed with HDPs helped to understand
their experiences and perceptions of their care from CHEWs, including their perceptions of their pregnancy
outcomes. Table 2 charts the data collected at baseline and endline.

Table 2: Data collection activities and number of participants
Intervention

CHEW interviews
Clients enrolled with HDP
IDIs with women with HDPs
(subset of enrolled clients)
Facility Inventory

Baseline

PostTraining

43

36

Comparison

Endline

Baseline

PostTraining

36*
40

29

0

25
20

20

Endline
37+
14
9

20

20

*7 CHEWs were not available at endline: + 8 additional CHEWs in the comparison arm

DATA MANAGEMENT AND ANALYSIS
All completed questionnaires were transferred immediately to the Council’s Abuja office for data entry and
analysis. All hard copies of questionnaires, consent forms, and client case notes were sealed and stored in
secured, locked drawers at the Council office. They will be stored for five years before being destroyed.
Data were analyzed with STATA, presented in frequency tables. To answer “Are lower level service providers
able to identify, classify, and manage hypertensive disorders in pregnant women and manage
appropriately with alpha methyldopa?”, a chi-square/Fisher’s exact test determined associations among
categorical variables. A non-linear difference in difference analysis determined the intervention’s effects
while accounting for baseline differences. P-values <0.05 are considered statistically significant.
Outcomes such as how well HDP was controlled, CVA incidence, and maternal and fetal survival were
assessed. Analysis considered whether CHEWs correctly diagnosed and categorized HDPs, as well as
women’s gestation at initial ANC, diagnosis, and study enrolment. Women diagnosed with moderate
hypertension and severe PE/E were interviewed to ascertain whether they received anti-hypertensive drugs
9

and MgS04, as appropriate. Women referred to higher facilities for definitive management were reported
upon, and women’s gestation at delivery, fetal and maternal outcomes were determined.
To evaluate clients’ quality of care, tests of association were conducted, looking closely at client case notes.
Qualitative data from IDIs with women who experienced PE/E were digitally recorded, transcribed,
translated, and analyzed to understand women’s perspectives about their quality of care from CHEWs at
PHCs as well as at referral facilities.

ETHICAL REVIEW AND CONSENT
Ethical approval of this study’s protocol was obtained from the Population Council’s Institutional Review
Board (IRB Protocol 760) in New York, in addition to the National Health Research Ethics Committee
(NHREC) at the Federal Ministry of Health (FMoH) in Nigeria as well as the Ebonyi State Research Ethics
Committee (MOH/ET/POP/0022/16). All participants (CHEWS and enrolled women) provided their own
informed consent for enrollment and subsequent interviews. Administrative and collaborative approval was
obtained from Ebonyi’s SMoH and LGA local health authorities.
Enrolled women’s information was documented by CHEWs, including telephone number and community
name, for ease of follow up. A doctor of medicine from SMoH provided quality control and followed up on
any adverse and serious adverse events during the study.
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RESULTS
The key findings from this intervention include the experiences and perspectives of clients enrolled in the
study. Table 3 describes basic the characteristics of participating CHEWs at both the intervention and
control PHCs, at baseline and endline. There were no significant socio-demographic differences between
the two arms, but their differences in work experience neared significance (P=0.05).

Table 3: CHEWs baseline and endline demographic characteristics
Characteristic

Intervention (n=79)

Comparison (n=66)

Baseline

Endline

Baseline

Endline

Baseline

Endline

(n=43)

(n=36)

(n=29)

(n=37)

(n=72)

(n=73)

93.1
6.9

97.3
2.7

90.3
9.7

93.2
6.8

0.2*

3.4
34.5
31.0
31.0

8.1
24.3
45.9
21.6

8.3
26.4
38.9
26.4

8.2
19.2
47.9
24.7

0.4

6.9
41.4
51.7

45.9
16.2
37.8

16.7
37.5
45.8

24.7
32.9
42.5

0.05

75.9

91.9

70.8

95.9

0.8

34.5

32.4

43.1

32.9

0.3

Gender, %≠
Female
88.4
88.9
Male
11.6
11.1
Age (years), %≠
15 - 25
11.6
8.3
>25 -35
20.9
13.9
>35 - 45
44.2
50.0
>45
23.3
27.8
≠
Work experience (years), %
< 1 year
23.3
2.8
1- 3 years
34.9
50.0
>3 years
41.9
47.2
RMNCH training in the last 3 years, %≠
Yes
67.4
100.0
Residence at facility, %≠
Yes
48.8
33.3
†

Total (n=145)

P-value†

Comparing intervention to control; * Fisher’s Exact test; ≠ Column percentages; RMNCH—reproductive, maternal, neonatal and child health

Table 4: Intervention effects on CHEW HDP management, intervention and comparison arms
CHEWs’ Management of HDPs
Correct description of BP measurement
CHEWs correctly defining HDP
CHEWs correctly grading hypertension
% of providers who properly described
how to manage BP
Knowledge of when to introduce
anti-hypertensive drugs
Knowledge of when to stop
anti-hypertensive drugs
Knowledge of when to rapidly lower
stroke risk in pre-eclampsic women
Knowledge of when to administer
MgS04 to pre-eclampsic women

Intervention

Comparison

Total

(n=79)

(n=66)

(n=45)

PValue‡

Marginal
effect^

46.2
57.9
20.0

<0.001
0.02
0.03

0.78
0.36
0.60

61

42.1

0.001

0.57

12.1

45

31.0

<0.001

0.38

4

6.1

35

24.1

0.03

0.52

43.0

17

25.8

51

35.2

0.008

0.49

50.6

21

31.8

61

42.1

0.02

0.41

n

%†

n

%†

n

%†

46
50
26

58.2
63.3
32.9

21
34
3

31.8
51.5
4.5

67
84
29

44

55.8

17

25.8

37

46.8

8

31

39.2

34
40

n/N*100. ‡P-value of the difference-in-differences estimate accounting for baseline differences in intervention and comparison arms;
P<0.05 considered statistically significant; ^ Average effect of training on CHEW HDP management in the intervention vs. comparison arm 1
†

1

i.e. A 0.78 marginal effect illustrates, on average, intervention CHEWs as 78 percentage points more likely to correctly describe BP
measurement
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Table 4 on the preceding page shows that the training’s implementation was followed by a change in
CHEWs’ knowledge and ability to manage HDPs.
Table 5 shows that CHEWs in the intervention arm had improved knowledge and abilities to distinguish
PE/E from other forms of hypertension than those in the comparison arm.

Table 5: CHEWs ability to distinguish between forms of hypertensive disorders in pregnancy across
intervention and comparison arms
Type of Hypertension

Intervention
(n=79)
n
%†

Comparison
(n=66)
n
%†

Total
(n=145)
n
%†

Chronic

34

43.0

16

24.2

50

34.5

Gestational

36

45.6

20

30.3

56

Pre-eclampsia

51

64.6

32

48.5

83

Severe pre-eclampsia
Eclampsia

32
55

40.5
69.6

18
44

27.3
66.7

50
99

34.5
68.3

P-Values‡

Marginal
Effect^

0.1

0.35

38.6

0.6

0.18

57.2

<0.001
_*
0.01

0.59
_*
0.41

* 72 observations not reported for this variable, hence no meaningful analysis; † n/N*100; ^ The average effect of the training on CHEWs
ability to distinguish types of HYPERTENSION in the intervention arm over the comparison arm; ‡ P-value of the difference-in-differences
estimate; accounting for baseline differences in the intervention and comparison arms; P<0.05 is considered statistically significant;
Significant results in bold

In both the intervention and comparison arms, CHEWs mostly identified alpha methyldopa and Nifedipine
as the drug of choice for controlling BP (Table 6). In addition, alpha methyldopa was the most prescribed
anti-hypertensive drug in both arms, however, prescription of this drug did not differ between the
intervention and control arms. At endline, almost no CHEW in either arm prescribed hydralazine, despite
intervention CHEWs’ awareness of it as a drug used to control BP.

Table 6: Prescribing practices among CHEWs in intervention and comparison arms2
Intervention
(n=79)
n
%‡
What specific drugs are used to control BP? †
Labetalol
alpha methyldopa/Aldomet
Nifedipine
Hydralazine
Aware/ever heard of alpha methyldopa?
Prescribe anti-hypertensive in facility
Most commonly prescribed anti-hypertensive≠
Labetalol
alpha methyldopa/Aldomet
Nifedipine
Hydralazine

Comparison
(n=66)
n
%‡

Total
(n=145)

n

%‡

P-valuea

7
39
37
9
54
47

8.9
49.4
46.8
11.4
68.4
59.5

5
20
26
9
39
33

7.6
30.3
39.4
13.6
59.1
50.0

12
59
63
18
93
80

8.3
40.7
43.4
12.4
64.1
55.2

0.7
0.02
0.4
0.7
0.2
0.25

13
23
7
2

27.7
48.9
14.9
4.3

1
14
10
3

3.0
42.4
30.3
9.1

14
37
17
5

17.5
46.3
21.3
6.3

0.006*
0.6
0.1
0.6*

† Multiple

response questions; ‡ n/N*100; * Fisher’s exact test; a Chi-square test, unless otherwise stated; ≠ Brand of anti-hypertensive to
be prescribed could be influenced by other facility level factors and not necessarily the intervention; Significant results in bold

2

Due to the multiple response questions and the low number of responses in this section, a difference in difference analysis accounting
for baseline differences in the intervention and comparison arms was not feasible. We recognize this as a limitation.
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MANAGEMENT OF WOMEN WITH HYPERTENSION IN PREGNANCY
There were no significant differences between the two study arms in gestational age at booking or
gestational age at diagnosis. We found a difference in gestational age at delivery between the two study
arms (P=0.02), but this difference may be due to the fewer women in the comparison arm (n=14).

Table 7: Women’s backgrounds, at enrolment, in intervention and comparison arms
Intervention
(n=40)
n (%)
Gestational age on booking
13 (32.5)
12-20 weeks
5 (21.5)
21-25 weeks
6 (15.0)
26-30 weeks
31-35 weeks
4 (10.0)
6 (16.0)
36-40 weeks
6 (15.0)
Did not report
Gestational age on diagnosis/enrollment
6 (15.0)
12-20 weeks
21-25 weeks
6 (15.0)
9 (22.5)
26-30 weeks
7 (17.5)
31-35 weeks
8 (20.0)
36-40 weeks
4 (10.0)
Did not report
Gestational age at delivery
5 (12.5)
<36 weeks
31 (77.5)
36 weeks and above
4 (10.0)
Did not record

Comparison
(n=14)
n (%)

(n=54)

Total

5 (35.7)
1 (7.1)
3 (21.4)
0 (0.0)
2 (14.3)
3 (21.4)

18 (33.3)
6 (11.1)
9 (16.7)
4 (7.4)
8 (14.8)
9 (16.7

3 (21.4)
1 (7.1)
3 (21.4)
4 (28.7)
3 (21.4)
0 (0.0)

9 (16.7)
7 (13.0)
12 (22.2)
11 (20.4)
11 (20.4)
4 (7.3)

6 (42.9)
5 (35.7)
3 (21.4)

11 (20.4)
36 (66.7)
7 (12.9)

P-value

n (%)

0.9*

0.2*

0.02*

Significant results in bold; * Fisher’s exact test

Following CHEWs’ training, only one client seen at an intervention PHC center was mis-classified for HDP
and its severity. By contrast, CHEWs in the comparison arm misclassified nine women (see Table 8,
following page).
Among women with moderate to severe hypertension requiring anti-hypertensive drugs upon diagnosis,
more women in the intervention arm received treatment (p<0.001). Furthermore, 50 percent of women
with severe pre-eclampsia in the intervention arm received a loading dose of MgSO4 upon diagnosis, while
no woman in the comparison arm received a MgSO4 loading dose (Table 8).
During this study’s duration, a total of five maternal deaths occurred—one in the intervention arm
(intrapartum death) and four in the comparison arm (one antepartum, 2 intrapartum, one postpartum). The
woman who died in the intervention arm did not receive a loading dose of MgSO4 after her diagnosis of
severe pre-eclampsia; all women who received a loading dose survived. A total of 13 fetal deaths also
occurred: four in the intervention arm (3 stillbirths, one early neonatal death) and nine in the comparison
arm (all stillbirths). No mothers of the infants who died received a loading dose of MgSO4.
These maternal and perinatal deaths were due to a combination of MgSO4 unavailability at facilities, at the
time of diagnosis of severe PE/E, and client failures to complete the referral process—and not receive the
drug. Upon study recruitment (immediately after diagnosis), only four women were given anti-hypertensive
drugs in the comparison arm, yet 29 in the intervention arm were. Similarly, of the women diagnosed with
severe PE/E at recruitment, only nine women were given MgSO4 (2 in the comparison arm and 7 in the
intervention arm).
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Table 8: Pregnancy outcomes among women with HDPs recruited, intervention and comparison
Pregnancy outcomes among women enrolled
with hypertension in study sites

Intervention
(n=40)
n (%)

Comparison
(n=14)
n (%)

Total
(n=54)

P-value

n (%)

Diagnosis at enrollment
1 (2.5)
1 (7.1)
2 (3.7)
Correctly Diagnosed Pre-Eclampsia
Correctly diagnosed Severe PE
15 (37.5)
0 (0.0)
15 (27.8)
21 (52.5)
1(7.1)
22 (40.7)
Correctly diagnosed Gestational Hypertension
<0.001*
2 (5.0)
3(21.4)
5 (9.3)
Correctly diagnosed Chronic Hypertension
Mis-classified
1 (2.5)
9(64.4)
10 (18.5)
Correct HDP classification at enrollment: mild, moderate, severe/chronic, gestational/PE, severe PE/E
37 (92.5)
1 (7.1)
38(70.4)
Yes
<0.001*
3 (7.5)
13 (92.9)
16 (29.6)
No
Received anti-hypertensive on diagnosis at recruitment for moderate to severe hypertension, severe PE/E
29 (72.5)
4 (28.6)
33 (61.1
Yes
0.002*
10 (71.1)
11 (27.5)
21 (38.9)
No
Received MgSO4 on diagnosis at enrollment
7 (17.5)
2 (14.3)
9 (16.7)
Yes
0.9*
33 (82.5)
12 (85.7)
45 (83.3)
No
Anti-hypertensive at first follow up after diagnosis of moderate to severe hypertension, severe PE/E
21 (60.0)
2 (18.2)
23 (50.0)
Yes
0.02*
14 (40.0)
9 (81.8)
23 (50.0)
No
Received MgSO4 on diagnosis at enrollment
Yes
5 (14.3)
2 (18.2)
7 (15.2)
0.8*
30 (85.7)
9 (81.8)
39 (84.8
No
8 (20.0)
2 (14.3)
10 (18.5)
Number of pregnant women referred
0.7
Fetal outcome
36 (90.0)
5 (35.7)
41 (75.9)
Alive
4 (10.0)
9 (64.3)
13 (24.1)
Dead
<0.001*
14 (100.0)
Total
40 (100.0)
54 (100.0)
Maternal outcome
39 (97.5)
10 (71.4)
49 (90.7)
Alive
0.004*
1 (2.5)
4 (28.6)
5 (9.3)
Dead
40(100.0)
14 (100.0)
54 (100.0)
Total
a Chi-square

test, unless otherwise stated; *Fisher’s exact test; Significant results in bold

More children survived with early administration of anti-hypertensive drugs to women with moderate to
severe hypertension, and a loading dose of MgSO4 to women with severe pre-eclampsia (p<0.005). No
women who received MgSO4 died in the intervention arm.

Table 9. Effects of MgSO4 and anti-hypertensive on fetal and maternal survival
Intervention
Comparison
Total
p-value
Diagnosed severe PE/E, received MgSO4 at enrollment—Fetal Survival
6 (85.7)
0 (0.0)
6 (66.7)
Alive
<0.001*
1 (14.3)
2 (100.0)
3 (33.3)
Dead
Total
7 (77.8)
2 (22.2)
9 (100.0)
Diagnosed moderate to severe hypertension, received anti-hypertensive at enrollment—Fetal Survival
Alive
20 (83.3)
1 (50)
21 (80.8)
4 (16.7)
1 (50)
5 (19.2)
Dead
0.003*
24 (92.3)
2 (7.7)
26 (100)
Total
Diagnosed moderate to severe hypertension, received anti-hypertensive at enrollment—Maternal Survival
24 (100)
2(100)
26(100.0)
Alive
0 (0.0)
0 (0.0)
0 (0.0)
Dead
_‡
24(92.3)
2(7.7)
26(100.0)
Total
*

Fisher’s Exact Test; ‡ No death in either arm, so no P-values could be computed
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FACILITY STOCK REVIEWS
A pre-post assessment of the 20 facilities from the comparison and intervention arms determined monthly
availability of commodities for effective HDP management (figures 2 and 3) over the implementation period
(December 2016 to November 2017). When Ending Eclampsia activities started in June 2016, stocks of
key supplies was generally poor (Figure 2). Most Ending Eclampsia facilities had no anti-hypertensive drugs,
calcium gluconate, urine test strips, etc. The project encouraged—and had impact upon—the stocking of
such commodities (Figure 2).
An industrial action (or workers’ strike) in June 2017 lasting about two weeks, an effort of the Joint Health
Sector Union (JOHESU—minus doctors) in Nigeria, lead to reduced supply availability. JOHESU is the largest
umbrella of the health workforce, therefore any attempt of industrial action can result in total facility
closures, leading to an inability for SMoH or Central Medical Stores to supply commodities. Consequently,
when the team visited to collect data during that period, not all facilities had resumed operation, despite
the resolution of the union to resume work.
Importantly, this period (June and July 2017) was characterized by extensive and massive health provider
transfers due to the introduction of PHCUOR (Primary Health Care Under One Roof policy) in Ebonyi, causing
another reduction in equipment and commodity availability. Some BP machines were not the property of
facilities but “privately owned,” and left when staff were transferred. In addition, from June until November
2017, some facilities reported damaged BP machines, which contributed to the reduced availability of
functional BP machines.
While all facilities had functional BP machines at baseline, there was a decline in their availability at endline.
Although stocks of urine test strips, calcium gluconate, MgS04, and anti-hypertensive drugs increased, the
trend indicates not all facilities consistently stocked these commodities and supplies. MgS04 appeared to
expire more frequently at facilities in the comparison arm, especially at baseline.

# of facilities with commodities in stock

Figure 2. Availability of commodities and supplies for detecting HDPs in comparison facilities,
June 2016 – November 2017
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Note: Facility assessment conducted in 20 PHCs
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Figure 3. Availability of commodities and supplies for detecting HDPs in intervention facilities
June 2016 – November 2017
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CLIENT ATTENDANCE AND SERVICES
More women attended facilities for ANC in the intervention arm (figures 4 and 5). Not every woman received
BP measurement or urine tests at each visit, although national standards stipulate that every woman
should be screened at every visit. Following the intervention, more women had BP and urine checked during
ANC visits than pre-intervention, and this consistently increased overtime: At first ANC visit, 94 percent of
women had BP measured, while 85 percent had a urine test.
Figure 4 shows that total BP measurement was slightly higher than total urine tested. Average monthly BP
measurement was 177 (standard deviation 57.5) and average monthly urine testing was 137 (standard
deviation 71.8).

Figure 4. Frequency of ANC visit and HDP screening at comparison facilities
June 2016 – November 2017
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Figure 5 illustrates greater total BP measurement than total urine tests. Average monthly BP measurement
was 433 (standard deviation 93.8) while average monthly urine testing was 307 (standard deviation
126.3).

Figure 5. Frequency of ANC visit and HDP screening at intervention facilities
June 2016 – November 2017
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WOMEN’S EXPERIENCES
This section draws upon qualitative interviews after the intervention with women who experienced PE/E, in
both the intervention (n=25) and comparison (n=9) sites. Transcripts were reviewed for correctness. The
team analyzed the transcripts for emerging themes, which resulted in categorization according to:
1. What women know about hypertension in pregnancy?.
2. Women’s perceptions about the content of their care
3. Women’s perceptions of provider prescription habits, commodity supplies, and follow up care
4. Women’s failure to complete referral processes due to inadequate information from facilities
5. Women’s perceptions of CHEWs’ care for hypertensive disorders at PHCs, and
6. Late ANC registration and inconsistent ANC impair early detection and management of HDPs.

WHAT DO WOMEN KNOW ABOUT HYPERTENSION IN PREGNANCY?
Women’s understanding and perceptions of HDP varied. Some thought that there are specific symptoms
that might provoke them to consider they had high BP. Even when symptoms occur (headaches, dizziness)
women tend to ascribe the symptoms to more familiar health conditions such as malaria in pregnancy.
“I felt it was malaria that I was having, and I started taking malaria drugs and after taking it, it did
not stop so I went to the health center where I registered for antenatal care, and they checked me
and told me that what I am suffering from is not malaria, but it is high blood pressure that I am
suffering from.”
HPD survivor, 22 years of age, multigravida, intervention arm
Some women could not recognize the onset of their hypertension, while some only realized it after they
were told by their health providers.
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“I didn’t know I had hypertension. My pregnancy was seven months when I started having
headache and fever. It was when I went to the maternity and they checked me and told me that I
have hypertension.”
HDP survivor, age 21, primigravida, comparison arm
Some women in the intervention arm were aware of negative consequences of HDPs, if not properly
managed, associating HDP with complications such as pre-term birth, miscarriage, maternal death, and
prolonged maternal morbidity. Women in the intervention arm better understood the need for careful
management of any hypertension to prevent complications and death.
“It could have made the baby to go to my heart or I could have delivered the baby when it is not
due for delivery or they will do it operation.” HDP survivor, age 30, multigravida, intervention arm
“Pregnant woman that is having blood pressure [hypertension], if not properly managed the
person’s child will die. [Health care workers] will start telling the pregnant woman another story.”
HDP survivor, age 32, multigravida, intervention arm

WOMEN’S PERCEPTIONS OF THE CONTENT OF THEIR CARE
Generally, but especially in intervention communities, women reported high satisfaction and favorable
opinions of their providers’ attitudes, both for them and their care. Overall, women in the intervention arm
reported improved care experiences, and many women seen at intervention facilities believe their care was
adequate. In both arms, women felt respected by their care providers, both at PHC and referral facilities.
“[The care provider] was very careful giving me blood pressure drugs when I come. Those health
providers used to take good care of me, if I come, they will start calling me with sweet names and
they use to play with me, they have good attitude towards me.”
HDP survivor, age 35, multigravida, intervention arm
“You know, the health provider that attended to me lives in our community, even though she’s not
originally from here; but she interacts with us very well, so when we come for antenatal care visits,
she treats us kindly to make us happy.”
HDP survivor, age 23, primigravida, comparison arm
This project used health talks and communication to improve women’s knowledge of important pregnancy
issues and empowered women to ask questions around their health and on any clinical and laboratory
findings. Similarly, women also reported increased communication between them and their care providers.
Women received health talks on their necessary health services and actions they should take in cases of
abnormal results.
“They used to give us health talks on different topics. What they teach today is not what they will
teach tomorrow, and that is the first thing they do before conducting health checks on us.”
HDP survivor, age 28, multigravida, comparison arm
“Yes, I used to feel very happy whenever I come for antenatal. After giving us a talk and I ask
questions and after answering me, I will be glad and when I am going, I will not be thinking about
anything.”
HDP survivor, age 30, multigravida, intervention arm
While client responses to health talks and communication were impressive, some clients were unhappy
with their care providers’ explanations of their clinical and laboratory test results. Some women recalled BP
results shared, but were not told about urine test results. In some cases, health care providers had informed
women of their test findings, but women could not recall them. Some women in the intervention arm feel
that health care providers intentionally do not communicate BP and urine tests results, especially when
findings are abnormally high. Providers on occasion do not reveal findings to clients even when symptoms
are severe enough to require referral.
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“You know, sometimes these nurses like to hide somethings for their patients. They don’t like telling
us- like now if my blood pressure is high, they won’t tell me my blood pressure is high, they will tell
me to go to somewhere else that is higher [higher level facility] than their own facility. That the
higher facility will treat me the way I am supposed to be treated. So, it’s all these things, sometimes
I will ask them what my blood pressure is? They will tell me not to worry, but I should go to
somewhere else that is not something they can handle again.”
HDP survivor, age 40, multigravida, intervention arm
“They checked my blood pressure, not urine. She did not tell me anything about my result. It was
when my husband asked them, ‘Why they are still keeping me?’ that the provider said my blood
pressure was high.”
HDP survivor, age 28, primigravida, comparison arm

WOMEN’S PERCEPTIONS OF PROVIDER PRESCRIPTION HABITS, COMMODITY
SUPPLIES AND FOLLOW UP CARE
Women in the intervention arm reported better prescription practices than those in the comparison arm.
Some women received appropriate anti-hypertensive drugs but did not know specifics about dosages or
frequency, and some felt it was usual for health care providers to not provide prescription specifics. Women
also complained that CHEWs sometimes instruct them to purchase their anti-hypertensive drugs from
outside sources due to lack of drug availability at facilities:
“I don’t know, you know, what they normally do in the hospital, is that they give you drugs without
telling you the name of the drugs. If the drugs names were written [prescribed] for me to go and
buy it, is then that I will know the names of the drugs. They just gave me [tablets], and I looked at
it and took [swallowed] it without knowing the names.”
HDP survivor, age 30, multigravida, intervention arm
“After those drugs and injections, they saw it was not working. It was then that they referred me to
Federal Medical Center.”
HDP survivor, age 30, multigravida, intervention arm
Some women who purchased their own drugs, from private sources, reported paying more than they could
afford. These women recommend the government ensure pro-poor, stable, and accessible drug supplies,
especially for pregnant women, to mitigate unaffordable health care.
“The medicine was costly. I paid gradually [in installment] when I don’t have money, but when I
had money I paid in full.”
HDP survivor, age 25, multigravida, comparison arm
“What I am telling the government is, for them to know how to improve this drug, so that it can
reach both the rich and the poor. They should be giving it to every pregnant mother, because there
are some that have finance problem. They should make it affordable for every pregnant woman.”
HDP survivor, age 27, multigravida, intervention arm

WOMEN’S FAILURE TO COMPLETE REFERRAL PROCESS—DUE TO INADEQUATE
INFORMATION FROM REFERRING FACILITIES
Issues with referrals to higher level facilities remain. While health providers made efforts to refer women to
for definitive management, some women did not visit referral facilities despite their continuous elevated
BP. This poses a challenge to PHC HDP management. Even when women complete their referrals, no
referral process provides continuity of care, especially a dual process reporting back to the PHC facility. As
a result, women often do not return to their originating PHCs for care after attendance and treatment at
referral facilities.
“Yes, I was referred to Federal Medical Center because of the high blood pressure, but I did not go
to where I was referred.”
HDP survivor, age 25, multigravida, intervention arm
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Women from both study arms failed to complete their referral process due to lack of detail and discussion
at their originating PHCs on the reasons for their referrals. These gaps in communication lead to declines
and non-adherence within the referral process. Some women complained of lack of financial reserves for
transportation to referral centers. CHEWs sometimes do not refer women to facilities closest to them.
Women often resort to borrowing to enable travel to referral centers.
“I usually enter okada [motorcycle] from Ogwor to Afikpo, I will say that it is far, as someone who
has nothing doing…we are just managing our best, we struggle to eat, he [husband] is trying his
best, anytime they said come, he will try to make sure that I go even if it means borrowing, he will
do so to ensure that I went.”
HDP survivor, age 30, multigravida, intervention arm
Sometimes women refused the recommended means of care. Some women were recommended for
hospital admission, but insisted on returning home due to lack of finances. Financial burdens are a
significant factor in whether women adhere to prescribed care (including referrals).
“When I got to Afikpo, they found out that I have high blood pressure. They said that they will give
me bedrest, I told them to allow me to go and look for money. I came back and spent two days at
the hospital.”
HDP survivor, age 36, multigravida, intervention arm

WOMEN’S PERCEPTIONS OF CHEWs’ CARE FOR HYPERTENSION IN PREGNANCY
Women in the intervention arm were accepting of CHEWs’ care provision. Some women mentioned CHEWs’
importance at PHCs, for attending to pregnant women, including HDP care. These women’s views reflect
CHEWs’ perceived respect for women’s dignity.
“Had it been that I didn’t come to this health center, I didn’t know what could have been the
condition of me and my baby, because this health center is really trying in to provide services. They
take care of pregnant women very well, especially in the area of hypertension.”
HDP survivor, age 27, multigravida, intervention arm

LATE ANTENATAL CARE REGISTRATION AND INCONSISTENT CONTACT IMPAIR
EARLY DETECTION AND MANAGEMENT OF HYPERTENSION IN PREGNANCY
Late ANC registration is still common. Generally, pregnant women’s first ANC contact is after 20 weeks’
gestation—in both study groups. Women also appear to simultaneously register in at least two facilities for
ANC. In some cases, women were already having complications by the time of their initial ANC at a facility:
“I know that I did not start antenatal on time. It was when I started feeling somehow [abnormal]
that my husband insisted that I should go to the maternity and register. By that time, I was six
months pregnant.”
HDP survivor, age 30, primigravida, comparison arm
In addition to registering for ANC at multiple facilities, women may also seek care from religious groups or
traditional birth attendants, due to pressure from friends and family.
“I went to the tradition medicine when I was pregnant, you know that if you have problem, many
people will be suggesting and advising you to go here or there, you will continue to move from one
place to another.”
HDP survivor, age 38, multigravida, comparison arm
“Let me tell you, I came here [PHC center] to confirm my pregnancy, and that was at 18 weeks, but
I’m used to receiving treatment at Mama Mgbo [a traditional birth attendant].”
HDP survivor, age 38, multigravida, comparison arm
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DISCUSSION
Given HDPs’ contribution to maternal and perinatal deaths in Nigeria 1-2, 6, coupled with the increasing
recognition that providers at lower levels (such as PHC) of the health system are a vital point of care for
women and children, this project aimed to test the feasibility of CHEWs to detect and manage HDP using
alpha methyldopa, as well as MgSO4 administration and referral in selected cases.
This study shows that CHEWs in the intervention sites were able to correctly measure BP and manage HDP.
CHEWs at intervention PHC centers were 60 percent more likely to correctly grade hypertension as mild,
moderate, or severe, an essential step for effective HDP management of women seeking lower level health
care. Those CHEWs were also better able to differentiate HDPs as chronic hypertension, gestational
hypertension, or pre-eclampsia. More women attended ANC in the intervention arm, but their BP was not
measured, nor urine tested, at every contact. While in resource-poor environments only testing urine for
proteinuria for BP over 140/90 may be understandable, there should be no excuse for not measuring BP
at every contact. A recent study of facility readiness in sub-Saharan Africa showed particularly poor abilities
to manage HDP, indicating that measurement of BP alone may not be adequate for quality care, however26.
CHEWs at intervention PHCs also appropriately prescribed alpha methyldopa to pregnant women with
moderately severe hypertension. Essential maternal health commodities such as MgSO4 and urine dipstick
were more frequently available at intervention facilities, indicating that the intervention affected and
improved the supply chain and logistics system. Although facilities in the comparison arm (as are all PHCs
in Nigeria) were already mandated by the national task shifting policy to provide a loading dose of MgSO4
and other basic obstetrics services, this intervention has demonstrated that it is possible to integrate an
additional service to more holistically manage women with HDPs.
CHEWs’ MgSO4 knowledge and use, for women with severe PE/E, improved by 55 percent. Half of all women
managed at intervention facilities were administered a loading dose of MgSO4, as opposed to none at
comparison sites. This provides the needed evidence and support to begin the empowerment of CHEWs to
provide these services more broadly at the PHC level in Nigeria, and in other places with a similar health
system structure. A similar study in Nigeria supports CHEW provision of a loading dose of MgSO4 to women
with severe PE/E8, 11.
Maternal and perinatal outcomes were better among women managed at intervention PHCs. The sample
sizes in both study groups (40 and 14 women, respectively) were too small for firm conclusions, but these
results show potential for this sort of PHC intervention. Where provider skills are enhanced, and essential
commodities become more available, health outcomes will consequently improve, as seen in this study,
and demonstrated in others27-29.
Women’s perceptions and experience of their use of PHC services were very encouraging. Women maintain
favorable opinions and that their CHEWs provided adequate information, through health talks on various
ANC issues, with cordiality by their providers30. CHEWs must, however, improve their communication of
critical information to clients, to accurately convey clients’ severity of condition to them. In some instances
CHEWs did not provide adequate information on use of drugs supplied or prescribed. Some women also
felt that CHEWs “concealed information” from them about their diagnoses, possibly due to the belief their
clients were better not knowing about their condition severity. If women and their families do not know or
understand how serious their medical conditions are, and their potential consequences, they may be less
likely to urgently seek care.
Local and state governments must fulfill their responsibilities for ensuring essential tools and commodities
are available—both at their points of need, and at all times.
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CONCLUSION
Community health extension workers at primary health care facilities can correctly measure blood pressure,
and detect abnormal blood pressure, and thereafter accordingly begin treatment for severe pre-eclampsia
and eclampsia and refer cases to higher level facilities for further management. Although challenges
remain in ensuring that enough commodities and supplies are continuously available, this study
demonstrates how ministries of Health can utilize these essential health workers, and arrest missed
opportunities, to detect pre-eclampsia—and potentially, other conditions—and prevent deterioration by
providing anti-hypertensives and magnesium sulphate to stabilize women with hypertensive disorders in
pregnancy and refer them for appropriate, and often life-saving, continuing treatment.

Recommendations—and Challenges—to Consider for Scale Up
 Disseminate findings to the Federal Ministry of Health and partners, to consider incorporation

within task shifting guidelines.
 The State Ministry of Health should ensure consistent commodities and supplies for managing

hypertensive disorders in pregnancy within primary health care.
 The importance of early care seeking in pregnancy and frequent checkups should be emphasized

to community members, especially through women’s groups.
 Community health extension workers should be updated in importance of information-sharing

with women and families.
 Women should be seen as active partners in their health care.
 Referral challenges needs within communities and local government areas need to be discussed.
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